KOCAA
VRDN icon

Knights of Columbus Asset Advisors’s Viridian Therapeutics VRDN Stock Holding History

Knights of Columbus Asset Advisors’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.3M Buy
70,553
+12,764
+22% +$206K 0.06% 260
2026
Q1 		$1.13M Sell
57,789
-237
-0.4% -$7.04K 0.06% 252
2025
Q4 		$1.81M Sell
58,026
-1,384
-2% -$38K 0.1% 205
2025
Q3 		$1.28M Buy
59,410
+1,386
+2% +$25K 0.07% 241
2025
Q2 		$811K Sell
58,024
-1,257
-2% -$17.1K 0.05% 256
2025
Q1 		$799K Buy
59,281
+1,570
+3% +$26.7K 0.06% 243
2024
Q4 		$1.11M Buy
57,711
+146
+0.3% +$3.17K 0.07% 236
2024
Q3 		$1.31M Sell
57,565
-22,409
-28% -$366K 0.09% 226
2024
Q2 		$1.04M Buy
79,974
+1,152
+1% +$15.9K 0.07% 258
2024
Q1 		$1.38M Sell
78,822
-75,127
-49% -$1.46M 0.1% 231
2023
Q4 		$3.35M Buy
153,949
+124,396
+421% +$1.96M 0.22% 195
2023
Q3 		$453K Buy
29,553
+823
+3% +$15.7K 0.04% 272
2023
Q2 		$683K Buy
+28,730
New +$737K 0.06% 263

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Knights of Columbus Asset Advisors's VRDN Position: Q2 2026 in Review

Knights of Columbus Asset Advisors increased its Viridian Therapeutics (VRDN) stake by 22% in Q2 2026, buying an estimated $206K and bringing the position to 70,553 shares worth $1.3M. The position accounts for 0.06% of the portfolio, ranked #260.

Knights of Columbus Asset Advisors first reported a position in VRDN in Q2 2023 and has held it in 13 quarters since. The position peaked at $3.35M in Q4 2023. 212 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • Knights of Columbus Asset Advisors held 70,553 shares of Viridian Therapeutics worth $1.3M as of Q2 2026.
  • Knights of Columbus Asset Advisors bought 12,764 Viridian Therapeutics shares in Q2 2026, an estimated $206K.
  • Viridian Therapeutics made up 0.06% of Knights of Columbus Asset Advisors's portfolio in Q2 2026, its #260 holding.
  • Knights of Columbus Asset Advisors first reported a position in Viridian Therapeutics in Q2 2023 and has held it in 13 quarters since.
  • Knights of Columbus Asset Advisors's Viridian Therapeutics position peaked at $3.35M in Q4 2023.
  • 212 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Knights of Columbus Asset Advisors's 13F filing for Q2 2026, filed 31 Jul 2026.